Champion Biotech: Strategic Cooperation Agreement Adjusted with MSD.

Chia Tai Biological announced that on April 2, 2026, the company signed a "Revised and Restated Supply, Distribution, and Co-Promotion Agreement" with Merck Sharp & Dohme Corp. The original agreement will terminate on the effective date of the new agreement. The new agreement stipulates that Merck Sharp & Dohme will supply the company with three products, including the nine-valent HPV vaccine, and authorize the company to exclusively import, promote, and sell them in mainland China. There is no longer a specified basic purchase amount, and instead, the purchase plan will be dynamically negotiated based on market demand. The cooperation period is until December 31, 2028, with the option to extend for two years. This adjustment will help deepen the strategic cooperation between the two parties, enhance risk resistance capability, alleviate operational pressure, and have no impact on the company's business independence.